Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $0.20 USD
Change Today +0.065 / 48.15%
Volume 772.4K
IMUN On Other Exchanges
Symbol
Exchange
OTC US
OTC US
Berlin
As of 8:10 PM 07/31/15 All times are local (Market data is delayed by at least 15 minutes).

Executive Profile*

Ronald B. Herberman M.D.

Former Chief Medical Officer, Senior Vice President of Research & Development and Director of Medical Research & Development, Immune Therapeutics, Inc.
AgeTotal Calculated CompensationThis person is connected to 0 board members in 0 different organizations across 5 different industries.

74--
As of Fiscal Year 2013

Background*

Mr. Ronald B. Herberman, M.D served as an Advisor of TNI Pharmaceuticals, Inc. Dr. Herberman served as Chief Medical Officer and Senior Vice President of Research & Development at TNI BioTech, Inc. since September 6, 2012 and served as its Director of Medical Research & Development. He served as the Chief Medical Officer of Oncology at Intrexon Corporation since September 1, 2009. Dr. Herberman served as a Director of Celsense, Inc. Dr. Herberman served as a Member of ...

Read Full Background

Corporate Headquarters*

37 North Orange Avenue
Orlando, Florida 32801

United States

Phone: 888-613-8802
Fax: --

Board Members Memberships*

There is no Board Members Memberships data available.

Education*

MD
NYU Elaine A. and Kenneth G. Langone Medical Center

Other Affiliations*

Annual Compensation*

There is no Annual Compensation data available.

Stock Options*

There is no Stock Options data available.

Total Compensation*

There is no Total Compensation data available.
*Data is at least as current as the most recent Definitive Proxy.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
IMUN:US $0.20 USD +0.065

COMPETITOR COMPENSATION

NamePosition/
Company
Compensation
John W. Varian Chief Executive Officer and Director
XOMA Corporation
$569.5K
Simon E. Moroney Ph.D.Chairman of Management Board and Chief Executive Officer
Morphosys AG
€751.2K
Charles G. Marianik Chairman of the Board, Chief Executive Officer and President
Horiba Scientific
$219.0K
David L. Hallal Chief Executive Officer and Director
Alexion Pharmaceuticals, Inc.
$696.1K
Compensation as of Fiscal Year 2014.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact IMMUNE THERAPEUTICS INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.